Fulgent Genetics Inc (FLGT)

Cash ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Cash and cash equivalents US$ in thousands 55,144 58,042 65,111 54,677 97,473 84,076 58,348 66,172 79,506 168,770 138,780 353,069 164,894 214,877 100,461 151,461 87,426 53,031 2,431 9,302
Short-term investments US$ in thousands 202,962 155,027 246,595 251,018 326,681 383,726 400,083 805,146 773,377 749,236 376,622 725,227 770,652 255,102 676,578 258,317 344,443 50,939 18,530 61,322
Total current liabilities US$ in thousands 72,899 73,990 75,751 75,949 73,018 61,421 64,819 107,848 116,178 124,385 127,527 152,630 112,840 147,158 129,130 196,530 131,074 60,356 8,872 7,953
Cash ratio 3.54 2.88 4.11 4.03 5.81 7.62 7.07 8.08 7.34 7.38 4.04 7.06 8.29 3.19 6.02 2.09 3.29 1.72 2.36 8.88

December 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($55,144K + $202,962K) ÷ $72,899K
= 3.54

The cash ratio of Fulgent Genetics Inc has shown fluctuations over the period from March 31, 2020, to December 31, 2024. The cash ratio measures the company's ability to cover its current liabilities with its cash and cash equivalents. A higher cash ratio indicates a stronger ability to meet short-term obligations.

Initially, the cash ratio was high at 8.88 on March 31, 2020, demonstrating a strong liquidity position. However, it decreased significantly to 1.72 by September 30, 2020, which could indicate potential liquidity challenges or a decrease in cash holdings relative to current liabilities.

Subsequently, the cash ratio improved to 8.29 by December 31, 2021, reaching a similar high level as in March 2020. This suggests a recovery in liquidity or an increase in cash reserves. However, the ratio fluctuated in the following periods but generally remained above 2, indicating adequate liquidity levels to cover short-term obligations.

The cash ratio peaked at 8.08 on March 31, 2023, before gradually decreasing to 3.54 by December 31, 2024. While the ratio experienced some volatility, it generally remained at levels that indicate Fulgent Genetics Inc has a sufficient amount of cash to cover its short-term liabilities.

Overall, the trend in the cash ratio for Fulgent Genetics Inc reflects fluctuations in its liquidity position over the analyzed period, with some periods showing stronger liquidity and others indicating potential challenges that may need monitoring and management attention.